


SB-747651A

Cat. No.:	HY-114038
CAS No.:	607372-46-3
Molecular Formula:	C ₁₆ H ₂₂ N ₈ O
Molecular Weight:	342.4
Target:	p38 MAPK
Pathway:	MAPK/ERK Pathway
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SB-747651A is an ATP-competitive mitogen- and stress-activated kinase 1 (MSK1) inhibitor with an IC ₅₀ of 11 nM. SB-747651A also inhibits PRK2, RSK1, p70S6K and ROCK-II. SB-747651A can be used for inflammation research ^[1] .												
IC₅₀ & Target	IC ₅₀ : 11 nM (MSK1) ^[1]												
In Vitro	<p>SB-747651A (5 μM; neutrophils) affects CXCL2-induced intraluminal crawling of neutrophils in a Mac-1-dependent manner. SB-747651A thwarts the intraluminal crawling of adherent neutrophils to optimal sites of emigration. SB-747651A (5 μM; neutrophils) significantly increases transmigration time and detachment time. SB-747651A affects mechanisms that regulate transendothelial migration of neutrophils in response to CXCL2 chemotactic gradient. SB-747651A inhibits the migration speed of extravascular chemotaxing neutrophils but does not affect their directionality in response to CXCL2 chemotactic gradient^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>												
In Vivo	<p>SB747651A (3 mg/kg; intrascrotal injection) results in increased neutrophil adhesion 3.5~4.5 hours following stimulation with CXCL2 as compared to the effect of CXCL2^[3].</p> <p>SB-747651A (3 mg/kg; i.p.) affects neutrophil extravasation by increasing neutrophil emigration only at 3 and 4 hours in mouse peritonitis model of acute inflammation^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Male C57BL/6N mice (8~16 weeks)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>3 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intrascrotal injection</td> </tr> <tr> <td>Result:</td> <td>Resulted in increased neutrophil adhesion 3.5~4.5 hours following stimulation with CXCL2 as compared to the effect of CXCL2.</td> </tr> <tr> <td>Animal Model:</td> <td>Male C57BL/6N mice (8~16 weeks)^[3]</td> </tr> <tr> <td>Dosage:</td> <td>3 mg/kg</td> </tr> </table>	Animal Model:	Male C57BL/6N mice (8~16 weeks) ^[1]	Dosage:	3 mg/kg	Administration:	Intrascrotal injection	Result:	Resulted in increased neutrophil adhesion 3.5~4.5 hours following stimulation with CXCL2 as compared to the effect of CXCL2.	Animal Model:	Male C57BL/6N mice (8~16 weeks) ^[3]	Dosage:	3 mg/kg
Animal Model:	Male C57BL/6N mice (8~16 weeks) ^[1]												
Dosage:	3 mg/kg												
Administration:	Intrascrotal injection												
Result:	Resulted in increased neutrophil adhesion 3.5~4.5 hours following stimulation with CXCL2 as compared to the effect of CXCL2.												
Animal Model:	Male C57BL/6N mice (8~16 weeks) ^[3]												
Dosage:	3 mg/kg												

Administration:	I.p.
Result:	Affected neutrophil extravasation by increasing neutrophil emigration only at 3 and 4 hours in mouse peritonitis model of acute inflammation.

REFERENCES

[1]. Feiner B, et al. Risperidone effects on heterochromatin: the role of kinase signaling. Clin Exp Immunol. 2019;196(1):67-75.

[2]. Hossain M, et al. The Specific Mitogen- and Stress-Activated Protein Kinase MSK1 Inhibitor SB-747651A Modulates Chemokine-Induced Neutrophil Recruitment. Int J Mol Sci. 2017;18(10):2163. Published 2017 Oct 17.

[3]. Shaista Naqvi, et al. Characterization of the cellular action of the MSK inhibitor SB-747651A. Biochem J. 2012 Jan 1;441(1):347-57.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA